
BLSM Stock Forecast & Price Target
BLSM Analyst Ratings
Bulls say
BlossomHill Therapeutics is a biopharmaceutical company focused on developing precision oncology treatments. With a promising pipeline and successful collaborations, they are well-positioned for growth in the biotech market. However, investors should be aware of the potential risks and volatility of the industry, as well as the uncertainties surrounding drug approvals and regulations. Despite these factors, BlossomHill shows potential for long-term success and growth in the lucrative cancer treatment market.
Bears say
BlossomHill Therapeutics is heavily reliant on its lead candidate, BH-30643, for future revenue generation and success, which has promising early results in TKI-naïve NSCLC patients with classical EGFR mutations. However, the company's potential success is not guaranteed, and additional capital may be needed in the future to fund operations. Risks associated with drug pricing and the fact that BlossomHill has never been profitable also contribute to this negative outlook.
This aggregate rating is based on analysts' research of Blossomhill Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BLSM Analyst Forecast & Price Prediction
Start investing in BLSM
Order type
Buy in
Order amount
Est. shares
0 shares